Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
BioCrowd.IO is an institutional research funding platform established to tackle the funding crisis in clinical and translational research. Founded in the United States, the organization aims to assist hospitals, universities, and patient communities in raising milestone-based capital when traditional grants fall short. The firm has developed a unique approach to funding that addresses the specific needs of the biotech sector.
Currently, BioCrowd.IO operates with a focus on unlocking capital from Donor-Advised Funds, venture philanthropy, and impact investing. The firm has positioned itself as a vital resource for R1 and R2 universities and hospital research organizations, providing them with alternative funding sources to support their innovative research initiatives. This approach is particularly relevant given the decreasing federal funding available for clinical research.
BioCrowd.IO concentrates on providing alternative funding sources specifically for clinical research. The firm targets R1 and R2 universities and hospital research organizations, which often face challenges in securing traditional funding. By unlocking capital from Donor-Advised Funds, venture philanthropy, and impact investing, BioCrowd.IO aims to bridge the funding gap in the biotech sector.
The platform is tailored for translational research, which is crucial for moving scientific discoveries from the lab to clinical applications. BioCrowd.IO seeks to support projects that demonstrate significant potential for impact in the healthcare field, particularly those that address pressing medical challenges.
BioCrowd.IO's portfolio includes several notable projects that highlight its commitment to advancing clinical research in the biotech sector. The following are key projects funded by the firm:
These projects reflect BioCrowd.IO's focus on funding innovative research that addresses critical health issues and contributes to advancements in medical science.
To pitch to BioCrowd.IO, founders should use the preferred channel available on their Contact Us page. It is important to include a comprehensive overview of the project, including funding needs and expected outcomes. Response times may vary, so founders should be prepared for potential follow-up discussions.
What are BioCrowd.IO's investment criteria?
BioCrowd.IO invests in clinical and translational research projects, specifically targeting R1 and R2 universities and hospital research organizations. The firm looks for projects that can demonstrate significant potential for impact in the biotech sector.
How can I apply or pitch to BioCrowd.IO?
Founders can submit their inquiries through the Contact Us page on BioCrowd.IO's website. It is advisable to provide a detailed overview of the project and its funding needs.
What makes BioCrowd.IO different from other investors?
BioCrowd.IO focuses on providing alternative funding sources for clinical research, particularly in response to the decreasing federal funding available. This unique approach allows them to support innovative projects that may struggle to secure traditional funding.
What is the geographic scope of BioCrowd.IO's investments?
BioCrowd.IO primarily invests in projects based in the United States, focusing on institutions that are engaged in clinical and translational research.
What is the typical check size for investments?
BioCrowd.IO typically invests between $250,000 and $900,000 in qualifying projects, depending on the specific needs and potential of the research initiative.
What kind of post-investment involvement does BioCrowd.IO have?
BioCrowd.IO maintains an active interest in the projects it funds, often providing ongoing support and guidance to ensure successful outcomes.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.